Back to top
more

Akebia Therapeutics (AKBA)

(Delayed Data from NSDQ)

$1.35 USD

1.35
1,739,772

+0.01 (0.75%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $1.35 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Akebia (AKBA) Stock?

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -6.25% and -2.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -70.00% and -11.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

New Strong Sell Stocks for May 12th

AKBA, CNA, EBMT, FCEL, and HMPT have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2021

Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD

Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Akebia (AKBA) Stock?

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session

Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Do Options Traders Know Something About Akebia (AKBA) Stock We Don't?

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Akebia Falls as Vadadustat Fails to Meet Safety Endpoint

Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.